KR102610425B1 - 대사적으로 최적화된 세포 배양 - Google Patents

대사적으로 최적화된 세포 배양 Download PDF

Info

Publication number
KR102610425B1
KR102610425B1 KR1020237008467A KR20237008467A KR102610425B1 KR 102610425 B1 KR102610425 B1 KR 102610425B1 KR 1020237008467 A KR1020237008467 A KR 1020237008467A KR 20237008467 A KR20237008467 A KR 20237008467A KR 102610425 B1 KR102610425 B1 KR 102610425B1
Authority
KR
South Korea
Prior art keywords
cell culture
cells
cell
culture
lactate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237008467A
Other languages
English (en)
Korean (ko)
Other versions
KR20230038324A (ko
Inventor
숀 로렌스
앤 킴
에이미 죤슨
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52813657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102610425(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20230038324A publication Critical patent/KR20230038324A/ko
Application granted granted Critical
Publication of KR102610425B1 publication Critical patent/KR102610425B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
KR1020237008467A 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양 Active KR102610425B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361889815P 2013-10-11 2013-10-11
US61/889,815 2013-10-11
PCT/US2014/059993 WO2015054554A1 (en) 2013-10-11 2014-10-10 Metabolically optimized cell culture
KR1020227003381A KR102510238B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003381A Division KR102510238B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양

Publications (2)

Publication Number Publication Date
KR20230038324A KR20230038324A (ko) 2023-03-17
KR102610425B1 true KR102610425B1 (ko) 2023-12-06

Family

ID=52813657

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020237008467A Active KR102610425B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양
KR1020227003381A Active KR102510238B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양
KR1020217011547A Active KR102358807B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양
KR1020167009163A Active KR102243980B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227003381A Active KR102510238B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양
KR1020217011547A Active KR102358807B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양
KR1020167009163A Active KR102243980B1 (ko) 2013-10-11 2014-10-10 대사적으로 최적화된 세포 배양

Country Status (17)

Country Link
US (2) US20160244725A1 (https=)
EP (3) EP3351620B1 (https=)
JP (3) JP6663854B2 (https=)
KR (4) KR102610425B1 (https=)
CN (2) CN114717196A (https=)
AU (2) AU2014331776B2 (https=)
CA (1) CA2926049C (https=)
DK (3) DK3351620T3 (https=)
EA (2) EA201991976A1 (https=)
ES (2) ES2678945T3 (https=)
HU (2) HUE039551T2 (https=)
IL (2) IL244511A0 (https=)
MX (2) MX384960B (https=)
PL (2) PL3055409T3 (https=)
SG (2) SG10201800772TA (https=)
WO (1) WO2015054554A1 (https=)
ZA (1) ZA201601550B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US20160244726A1 (en) * 2013-10-11 2016-08-25 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US20160244725A1 (en) 2013-10-11 2016-08-25 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
JP7260018B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260020B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260011B2 (ja) * 2017-03-31 2023-04-18 株式会社三洋物産 遊技機
JP7260009B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7260021B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7310945B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7310947B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
JP7260013B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7260012B2 (ja) * 2017-04-27 2023-04-18 株式会社三洋物産 遊技機
JP7272480B2 (ja) * 2017-04-27 2023-05-12 株式会社三洋物産 遊技機
JP7310952B2 (ja) * 2017-04-27 2023-07-19 株式会社三洋物産 遊技機
WO2019071076A1 (en) 2017-10-06 2019-04-11 Lonza Ltd. AUTOMATED CONTROL OF CELL CULTURE BY SPECTROSCOPY RAMAN
IL315801A (en) 2017-10-16 2024-11-01 Regeneron Pharma Perfusion bioreactor and methods of using it
EP3717656B1 (en) * 2017-11-30 2024-03-13 F. Hoffmann-La Roche AG Process for culturing mammalian cells
HRP20260157T1 (hr) * 2018-03-29 2026-03-27 F. Hoffmann - La Roche Ag Moduliranje laktogene aktivnosti u stanicama sisavaca
GB201810772D0 (en) * 2018-06-29 2018-08-15 Ge Healthcare Bio Sciences Ab Method in bioprocess purification system
JP7231355B2 (ja) * 2018-08-22 2023-03-01 日機装株式会社 細胞培養方法および細胞培養装置
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
JP2020151559A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
JP2020151560A (ja) * 2020-06-24 2020-09-24 株式会社三洋物産 遊技機
EP3985097A1 (en) * 2020-10-14 2022-04-20 Sartorius Stedim Biotech GmbH A method and system for configuring and/or setup of a downstream process for processing a biomass

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6165741A (en) 1997-05-30 2000-12-26 The Trustees Of The University Of Pennsylvania Method for rapid detection of bacterial growth in cultures
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US6953692B2 (en) * 2001-12-18 2005-10-11 Bayer Pharmaceuticals Corporation Device and method for seed-train expansion of mammalian cells
US7039770B1 (en) 2002-03-05 2006-05-02 Juniper Networks, Inc. Low latency request dispatcher
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
ATE472597T2 (de) 2003-05-15 2010-07-15 Wyeth Llc Kontrollierte glukosezufuhr für tierzellkultur
US7531327B2 (en) * 2004-07-23 2009-05-12 Immunomedics, Inc. Methods and compositions for increasing longevity and protein yield from a cell culture
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
BRPI0618178A2 (pt) * 2005-11-02 2011-08-23 Wyeth Corp métodos para adaptação de células de mamìferos
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
US7575890B2 (en) 2006-01-18 2009-08-18 Oxygen Enterprises, Ltd. Method for rapid detection and evaluation of cultured cell growth
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
UA106047C2 (uk) * 2008-06-13 2014-07-25 Сентокор Орто Байотек Інк. Спосіб отримання високої щільності життєздатних клітин в культурі клітин ссавців
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture
US9428727B2 (en) * 2010-04-26 2016-08-30 Novartis Ag Cell culture medium
PL2576580T3 (pl) * 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
TWI637057B (zh) 2012-11-09 2018-10-01 拜爾沙納有限公司 具交替生物反應器用途之不連續進料批次製程
US20150353542A1 (en) * 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
US20160244725A1 (en) 2013-10-11 2016-08-25 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BHANU CHANDRA MULUKUTLA et al., Metabolic Engineering (2011) 14(2):138-149
FRANCESCA ZAGARI et al., New Biotechnology (2013) 30(2):238-245

Also Published As

Publication number Publication date
US20210087535A1 (en) 2021-03-25
JP2022009453A (ja) 2022-01-14
EP3351620A1 (en) 2018-07-25
PL3351620T3 (pl) 2021-03-08
CA2926049A1 (en) 2015-04-16
ES2678945T3 (es) 2018-08-21
SG10201800772TA (en) 2018-03-28
ES2833471T3 (es) 2021-06-15
JP2020072760A (ja) 2020-05-14
DK3055409T3 (en) 2018-07-30
MX384960B (es) 2025-03-14
KR102510238B1 (ko) 2023-03-16
MX376623B (es) 2025-03-07
DK3812453T3 (da) 2026-04-13
WO2015054554A1 (en) 2015-04-16
MX2020011334A (es) 2021-07-30
AU2021200193B2 (en) 2023-08-24
IL244511A0 (en) 2016-04-21
KR20210046835A (ko) 2021-04-28
IL262833A (en) 2018-12-31
EA033783B1 (ru) 2019-11-25
KR20160062032A (ko) 2016-06-01
EP3351620B1 (en) 2020-09-02
HK1253275A1 (en) 2019-06-14
MX2016004564A (es) 2016-07-12
KR20220020415A (ko) 2022-02-18
AU2021200193A1 (en) 2021-03-18
EA201991976A1 (ru) 2020-04-02
EA201690600A1 (ru) 2016-09-30
AU2014331776B2 (en) 2020-10-22
HUE039551T2 (hu) 2019-01-28
DK3351620T3 (da) 2020-10-26
EP3055409A4 (en) 2016-09-28
CN105637085A (zh) 2016-06-01
JP6663854B2 (ja) 2020-03-13
HK1223122A1 (en) 2017-07-21
CN114717196A (zh) 2022-07-08
AU2014331776A1 (en) 2016-03-24
SG11201601681QA (en) 2016-04-28
JP7377243B2 (ja) 2023-11-09
CA2926049C (en) 2023-09-05
JP6967620B2 (ja) 2021-11-17
HUE051049T2 (hu) 2021-01-28
EP3055409B1 (en) 2018-04-25
EP3055409A1 (en) 2016-08-17
KR102358807B1 (ko) 2022-02-08
KR102243980B1 (ko) 2021-04-26
JP2016532457A (ja) 2016-10-20
EP3812453B1 (en) 2026-03-25
EP3812453A1 (en) 2021-04-28
ZA201601550B (en) 2023-05-31
PL3055409T3 (pl) 2018-10-31
US20160244725A1 (en) 2016-08-25
KR20230038324A (ko) 2023-03-17

Similar Documents

Publication Publication Date Title
JP7377243B2 (ja) 代謝が最適化された細胞培養
US12545717B2 (en) Metabolically optimized cell culture
US20160244726A1 (en) Metabolically optimized cell culture
HK40042432A (en) Metabolically optimized cell culture
HK1253275B (en) Metabolically optimized cell culture
EA040764B1 (ru) Метаболически оптимизированная клеточная культура
HK1223122B (en) Metabolically optimized cell culture
EA045030B1 (ru) Метаболически оптимизированная клеточная культура
BR122024020665A2 (pt) Método para cultivar células, e, célula hospedeira metabolicamente alterada
BR122024020669A2 (pt) Método para cultivar células, e, célula hospedeira metabolicamente alterada
BR112016007739B1 (pt) Método para cultivar células

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601